Voor de beste behandeling van patiënten met kanker, werken we samen met onderzoekers en behandelaars in heel Nederland.

Hartwig Medical Foundation helpt het ontstaan van kanker en de behandeling daarvan beter te begrijpen.

Hartwig Medical Foundation verzamelt genetische en klinische gegevens en stelt deze beschikbaar voor onderzoek.

Het ultieme doel is dat elke patiënt een gepersonaliseerde behandeling krijgt, gebaseerd op het DNA van de tumor.

Kom ik in aanmerking voor een uitgebreide DNA-test?

FOCUS GROUP UROTHELIAL CANCER

Bladder cancer is a very common malignant tumor with approximately 7000 new cases/year in the Netherlands. The peak incidence is in the 7th decade and smoking is the most important risk factor. Muscle-invasive bladder is characterized by a high risk of metastatic spread and death from disease. Despite extensive treatment, consisting of cisplatin-based neoadjuvant chemotherapy, radical pelvic surgery or chemoradiation the outcome of muscle-invasive bladder cancer patients remains poor. Patients with metastatic disease have even worse outcomes although new treatment options are on the horizon.

Bladder cancer (urothelial carcinoma) is characterized by a high mutational burden but little is known about the clonal evolution of metastatic urothelial cancer. The urothelial cell cancer group will investigate the molecular mechanisms that drive the high metastatic potential of urothelial cancer. In addition, predictive markers that correspond to response to systemic therapy are urgently needed both in the neoadjuvant and metastatic setting because only a proportion of the patients treated show a response. In case of immunotherapy by checkpoint inhibition, which is very costly, durable responses have been reported in urothelial cancer patients but the molecular background of these longstanding responses have not been clarified yet.

The focusgroep aims:

  • to clarify the molecular mechanisms responsible for the high metastatic potential of urothelial cancer;
  • to identify predictive molecular markers of urothelial cancer that correspond with response to systemic treatment;
  • to identify potential targets for new and existing therapies of urothelial cancer.
Chair

Joost Boormans, Erasmus MC

For more information, e-mail info@hartwigmedicalfoundation.nl